Compass Pathways' latest update reveals extended trial timelines, staff cuts, and financial concerns, raising questions about ...

Shuttle Pharmaceuticals (NASDAQ: SHPH), a rising force in cancer treatment innovation, has experienced a notable boost in its ...

Two novel peptides derived from Protagonist's proprietary discovery platform are in advanced Phase 3 clinical development ... the timing of JNJ-2113 and rusfertide clinical trials, and timing of ...

Nkarta is working on engineered NK cell therapies for autoimmune diseases and cancer. Click here to find out why I maintain a ...

Journey Medical (NASDAQ:DERM) shares are trading higher Monday after the company announced the U.S. Food and Drug ...

Europe has been falling behind on clinical trials over the past decade as pharmaceutical companies shift their focus to the ...

Nov. 5, 2024 /PRNewswire-PRWeb/ -- BioFactura, Inc. recently announced contract option activations totaling $7.8 million by the Biomedical Advanced Research and Development ... completed activities ...

Real-time index price for S&P 500 Consumer Staples [Sector] (SRCS), along with buy or sell indicators, analysis, charts, ...

Nov. 4, 2024 /PRNewswire/ -- Movano Health (NASDAQ: MOVE) announced today that it has submitted a complete response package to the FDA as part of the final phase of the ... in remote patient ...

Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L and petosemtamab monotherapy in 2/3L r/m HNSCC enrolling Petosemtamab in 2L+ r/m HNSCC interim clinical ...

The patent strengthens the intellectual property portfolio of FemBloc, Femasys's flagship therapeutic product candidate, which is currently in the pivotal phase of clinical trials. FemBloc ...